Search Results - paul+erhardt

4 Results Sort By:
Compounds for non-lethal micropinocytosis and exosome production
Project ID: D2017-25 Background Exosomes are vesicles in the range of 30 to 120nm, which are released from mammalian cells when multi-vesicular endosomes fuse with the plasma membrane. In recent times, exosomes have been implicated in cancer. Mounting evidence suggests that exosomes play an important role in mediating intercellular communication...
Published: 6/18/2024   |   Inventor(s): William Maltese, Paul Erhardt, Zehui (Lesley) Li, Christopher Trabbic
Keywords(s): Cancer, Exosome, Vacuole, Vesicle
Category(s): Neuroscience, Oncology, Diagnostics
Compounds for disrupting microtubule networks and mitosis in brain cancer
Project ID: D2014-42 Background Primary brain tumors and secondary intracranial tumors from metastatic spread of other cancers (e.g., melanoma, lung carcinoma) have been inaccessible to therapy with microtubule-targeted agents (vincristine, vinblastine, paclitaxel) because the latter do not readily cross the blood-brain barrier. Invention...
Published: 6/18/2024   |   Inventor(s): William Maltese, Paul Erhardt, Christopher Trabbic, Jean Overmeyer
Keywords(s):  
Category(s): Neuroscience, Oncology
Cancer Therapy via Simultaneous Non-apoptotic Cell Death Mechanisms
Project ID: D2018-15 Background Most of current cancer therapy employs drugs that act through apoptotic signaling pathways. However, cancer cells often acquire mutations that can diminish apoptosis and lead to chemo-resistance when coupled with increased capacity for drug efflux and DNA repair. This results in chemotherapeutic failure especially...
Published: 6/18/2024   |   Inventor(s): Amit Tiwari, Chandrabose Karthikeyan, Haneen Amawi, Paul Erhardt, Piyush Trivedi
Keywords(s): Autophagy, Cancer, Drug-resistance, Methuosis, Non-apoptotic cell death
Category(s): Oncology
Advancement in Platinum Based Cancer Therapeutics
Project ID: D2014-33Novelty: Small drug like molecules that inhibits DNA repair factors for cisplatin (and other platinum based drugs) resistance towards solid tumors, thereby increasing cisplatin cytotoxicity and efficacy. Value proposition: One of the limitations of chemotherapy in ovarian cancer is the innate/acquired drug resistance in cancer cells....
Published: 6/18/2024   |   Inventor(s): Paul Erhardt, Stephan Patrick, Christopher Trabbic
Keywords(s): Cisplatin, Clinical Trials, DNA Repair, Ovarian Cancer, Platinum
Category(s): Oncology, Tools